...
首页> 外文期刊>Systematic Reviews >Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature
【24h】

Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature

机译:药物事实利益攸关方传达的不良药物反应的信号:议定书,了解全球文献的范围审查

获取原文

摘要

Signals of adverse drug reactions (ADRs) form the basis of some regulatory risk-minimization actions in pharmacovigilance. Reviews of limited scope have highlighted that such signals are mostly supported by reports of ADRs or multiple types of evidence. The time that elapses between a report of a suspected ADR and the communication of a signal has not been systematically characterized. Neither has the features of reports of suspected ADRs that authors used to support putative causal relationships, although difficulties with establishing causal relationships between medicinal products and adverse events have been highlighted. The objectives of this study will be to describe the evidence underpinning signals in pharmacovigilance, the features of reports of ADRs supporting signals, and the time that it takes to communicate a signal. We shall retrieve records from PubMed, EMBASE, Web of Science, and PsycINFO (from inception onwards), without language/design restrictions, and apply backward citation screening. We shall hand-search the websites of 35 regulatory agencies/authorities, restricted publications from the Uppsala Monitoring Centre, and drug bulletins. Signals will be requested from the competent stakeholder, if absent from websites. We shall use VigiBase, the World Health Organization’s Global Individual Case Safety Report database, to determine the dates on which ADRs were reported. We shall manage records using EndNote (v. 8.2); one reviewer will screen titles/abstracts and full texts, a second will cross-validate the findings, and a third will arbitrate disagreements. Data will be charted via the Systematic Reviews Data Repository, following the same procedures as for data retrieval. Evidence will be categorized according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. Features of reports of ADRs will be coded. Tables will display frequencies of types of evidence and features of reports of ADRs. We shall use plots or pictograms (if appropriate) to represent the time from the first report of a suspected ADR to a signal. We expect the findings from this review will allow a better understanding of global patterns of similarities or differences in terms of supporting evidence and timing of communications and identify relevant research questions for future systematic reviews.
机译:不良药物反应(ADRS)的信号构成药物检测中一些监管风险最小化行动的基础。有限范围的评论强调,此类信号主要由ADRS或多种证据报告提供支持。涉及疑似ADR的报告与信号通信之间的时间尚未得到系统特征。既没有疑似ADR的报告的特征也不是支持推定的因果关系的作者,尽管已经突出了药品和不良事件之间建立因果关系的困难。本研究的目标将是描述药物检测中的证据,ADRS支持信号的报告的特征以及传送信号所需的时间。我们将检索来自PubMed,Embase,Science Web和Psycinfo(从起始)的记录,没有语言/设计限制,并申请向后引用筛选。我们将以乌普萨拉监测中心和毒品公报从35名监管机构/当局的网站上搜索35个监管机构/当局的网站和限制出版物。如果缺席网站,将从主管利益相关方请求信号。我们将使用World World Healtom组织全球案例安全报告数据库的Vigibase,确定ADRS报告的日期。我们将使用Endnote管理记录(v.8.2);一个审阅者将屏幕/摘要和全文屏幕,第二个将交叉验证调查结果,第三个将仲裁分歧。数据将通过系统评论数据存储库进行绘制数据,以与数据检索相同的程序。证据将根据牛津中心进行分类,以获取基于证据的证据水平。将编码ADR的报告的功能。表将显示ADR报告的证据类型和功能的频率。我们将使用绘图或象形图(如果合适)将疑似ADR的第一报告的时间代表到信号。我们预计本次审查的调查结果将在支持沟通证据和时机的支持方面更好地了解全球相似性或差异,并确定未来系统评价的相关研究问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号